For every tomorrow
CureGBM - Advancing Sonodynamic Therapy for Brain Tumors
Building the European pathway for a treatment that should already exist.
We Are CureGBM
WHO WE ARE
CureGBM is a clinical-stage MedTech company founded by siblings Richard Wakefield and Jane Oberholzer after losing their father to glioblastoma in 2021. We are not a charity.
We are building the commercial, clinical, and regulatory infrastructure to bring Sonodynamic Therapy – a transformative brain tumour treatment –Â to European patients, in time to make a difference to people with this condition today.
WHAT WE DO
We are advancing Sonodynamic Therapy (SDT) for glioblastoma. SDT uses focused ultrasound to activate 5-ALA, a drug that selectively accumulates in brain tumour cells, causing them to self-destruct while leaving healthy tissue untouched. External Phase 1 studies in the United States have already demonstrated a doubling of median survival in patients with recurrent GBM, with no therapy-related adverse events.
WHY WE EXIST
The standard of care for GBM has not meaningfully changed in thirty years: surgery, radiotherapy, chemotherapy. The evidence for something better already exists. What has not existed, until now, is a European pathway to reach it. We are building that pathway.Â
MISSION STATEMENT
CureGBM exists to close the European care gap for brain tumour patients by bringing Sonodynamic Therapy to market. We connect the clinical, regulatory, and commercial infrastructure needed to deliver this transformative treatment to the people who need it, when it can still make a meaningful difference.
Services
Choose your Journey
02
Clinician overview of SDT, its scientific basis, and upcoming clinical trial pathway.
03
CureGBM has a patient advocate, Jane Oberholzer, who will be able to answer any questions you may have about the trial and direct any medical queries to the relevant clinicians involved in the trial.
Announcing
2026 Trial of Sonodynamic Therapy for GBM
Patient-Centric Approach
This safety trial is for people with Glioblastoma (GBM) that have previously been treated with maximal resective surgery, radio- and chemotherapy. Patients must be independent of daily activities, aged over 18 years old, and not part of another research trial / experimental treatment.
Medical Mission
Despite surgery and chemo/ radiotherapy, almost all GBM tumours recur (recGBM), at which point survival drops to just 6-8 months. For children diagnosed with DIPG / DMG, the prognosis is even more devastating – typically no more than 9 months after radiotherapy. Early SDT trials in the USA have shown average survival to double after SDT treatment: to 14 months for recGBM, and 16 months for DIPG / DMG – with no side effects from therapy - even with repeated monthly treatments.
Expertise You Can Trust
We strongly believe outpatient-delivered SDT treatments represent a transformative leap in neuro-oncology - a powerful third-line therapy which could redefine care and restore hope for patients and families facing these relentless diseases.
Enrol Data
The trial will be in Bern, Switzerland starting in 2026. Initial enquiries can be made to the team at CureGBM via the contact form. The information will be held and you will be contacted by the enrollment team from Bern when trial eligibility opens.
Explore powerful stories of hope
Our patients success stories
Duncan Campbell
New York
Why We Fight for Better Treatment Access
Duncan Campbell was 27, living his best life with his career and social life full of hope, when diagnosed with glioblastoma in February 2021. We learned that on average, he had around 14 months to live and he grieved the “theft” of his future.
Despite poor prognostic features, he lived 3 and a half years until August 2024. And every extra month, every extra day, mattered.
In December 2023, Dunk and his family headed to New York for a sonodynamic therapy trial. Before the treatment, Dunk could barely walk 100 metres and was stopped by pain. He had lost most of his vision and was using a white stick.
After just one session of sonodynamic therapy, he improved. Unlike all conventional treatments, the treatment didn’t make him ill, didn’t immuno-suppress, nor give him ulcers or tire him. Effectively no downside.
Within days he walked unaided up to five miles a day through New York. His vision improved. He felt creative again for the first time in years.
But those months he gained—those walks through New York, those moments of clarity, that time with his family—they mattered.
This is why it’s our mission.
To bridge the gap between breakthrough treatments and the patients who need them. To make sonodynamic therapy accessible so families don’t have to fly across the world for a chance restricted by irrelevant red tape in their home country.
Aunty M Brain Tumours Talk Show
Interview with Richard and Jane
Jane Oberholzer and her brother Richard Wakefield founded CureGBM after losing their dad to glioblastoma in 2021—just five weeks after his operation.
We sat down with Aunty M Brain Tumours Talk Show to share our story. Why we started CureGBM. What happened when our dad was diagnosed with glioblastoma in 2021. How we discovered sonodynamic therapy and realized it wasn’t available in Europe. And why we decided to stop waiting and build the pathway ourselves.
Voices
Our mission is Personal...
Team
Richard Wakefield
Founder CureGBM
Jane brings a deeply personal and compassionate perspective to CureGBM as its dedicated Patient Advocate. Having lived and worked in both London and Zurich, she balances a demanding career in asset management with a rich family life and active involvement in community philanthropy. Her commitment to CureGBM is rooted in her own experience – when her father was diagnosed with glioblastoma (GBM), she faced the journey with minimal support. Today, she channels that experience into being a steady, empathetic presence for patients and families navigating the same path.
Jane Oberholzer
Patient Advocate CureGBM
Contact us today
Making the impossible possible.
Initial enquiries can be made to the team at CureGBM. Fill out the form here.
- UK ⎥ SWITZERLAND ⎥ ITALY